Interleukin-2 receptor alpha-chain (CD25) expression on leukaemic blasts is predictive for outcome and level of residual disease in AML

M. Terwijn, N. Feller, A. van Rhenen, A. Kelder, G.A. Westra, S. Zweegman, G.J. Ossenkoppele, G.J. Schuurhuis

Research output: Contribution to journalArticleAcademicpeer-review

63 Citations (Scopus)


We investigated the role of CD25 as a prognostic marker in acute myeloid leukaemia (AML). Seventy-two newly diagnosed patients ≤60 years were retrospectively analysed by flow cytometry for CD25 positivity of AML blasts. Patients with CD25 expression of >10%, when compared to ≤10%, had a significantly shorter overall survival (OS, p = 0.0005) and relapse-free survival (RFS, p = 0.005). In multivariate analysis CD25 expression is an independent adverse factor for OS and RFS. High CD25 combined with FLT3-ITD positivity resulted in the poorest OS and RFS (p = 0.001 and p = 0.003, respectively). CD25 expression remained prognostic within the intermediate cytogenetic risk group. In addition, after the first cycle of chemotherapy, a significantly higher MRD frequency was found in patients expressing CD25 above cut-off (p = 0.003). Our results show that CD25 expression is an independent adverse prognostic marker in AML patients ≤60 and correlates with MRD. © 2009 Elsevier Ltd. All rights reserved.
Original languageEnglish
Pages (from-to)1692-1699
Number of pages8
JournalEuropean Journal of Cancer
Issue number9
Publication statusPublished - Jun 2009


  • Acute myeloid leukaemia
  • Flow cytometry
  • IL-2 receptor
  • Intermediate cytogenetics
  • Prognosis

Cite this